Indian companies have made acquisitions of $1 billion so far in January
The broader NSE Nifty too dived by 101.65 points, or 0.97 per cent, to close at 10,350.15.
The merger has fortified Sun Pharma's position.
Data also show that several other leading domestic pharma companies have recalled their products from the US
Currently, the spend on R&D as a percentage of GDP is just 0.9%
'From Doklam to Wuhan and the return of the India-China relationship to its previous equilibrium is indeed a major contribution of President Xi and PM Modi. Without any doubt they deserve the kudos for their sagacity and their wisdom,' says Ambassador Gautam Bambawale, India's envoy to China during the Wuhan summit.
India on Monday raised serious concerns over the USFDA's audit inspections of Indian pharma companies and 'disproportionate penalties' in some instances and said it would submit a discussion document on the issues to the US.
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
'This novel format of diplomacy -- the informal summit -- will not only facilitate bilateral communication and reduce miscalculations at the very top level of the two governments, but possibly open the space for China and India to speak in one voice on various issues of mutual concern,' note Feng Renjie and Ding Kun Lei
He said countries should work for promoting open and inclusive cooperation for win-win outcomes.
The Supreme Court on Monday posed some tough questions to a lawyer, asking him to substantiate his "unfounded allegations" in a PIL that Indian pharma major Ranbaxy Laboratories Ltd was allegedly manufacturing and selling adulterated medicines.
Among these, Hindalco and Vedanta from the metal pack have become multi-baggers, gaining 100 per cent in 2016
So far, India has attracted over $20 billion in the debt segment, thanks to the rate differential.
Neither pharma nor IT would have become the stars of the economy without the active but largely invisible hand of the Indian State, says Ajit Balakrishnan.
The news that exports to the US will not restart before next year as well as the September quarter performance are sentiment dampeners.
The European Medicines Agency's review is the second setback to Alkem Laboratories
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.
In 2013, Daiichi had launched the arbitration proceedings in Singapore.
Devangshu Datta highlights the silver lining for the long-term investor.
Once tipped to emerge as the biggest exporter, the pharmaceutical industry is yet to acquire the scale of those in software services, says Krishna Kant.
Sun Pharmaceutical's acquisition of Ranbaxy has received final approvals.
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
There isn't much Budget could do directly to help sectors.
The 1995 judgment in the Union of India vs Cricket Association of Bengal case emphasised that free speech is essential for a successful democracy and citizens must have a plurality of views and a range of opinions on all public issues, says M J Antony.
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
Through the past 12 months, the Bank Nifty has risen 55%
Sun Pharma stock has appreciated at 35% a year for 20 years
Lupin will fund the buy through $100 mn cash reserves and a bridge loan.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Since 2013, the FDA has banned around 30 Indian drug manufacturing units for various violations
Inspections only in domestic authorities' presence, visiting US drug regulator told
Wealth of the richest 62 people has risen 44% in the five years since 2010, while that of the bottom half fell by 41%
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
Select metal stocks rebounded while power stocks extended losses after SC verdict on coal block allocations.
Move could be aimed at integrating operations with Indian subsidiary.
It's difficult to understand if GDP growth has actually improved.
Expenditure on health in India is at a global low of 1.2% of GDP.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances